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Metal complexes designed to bind to amyloid-b
for the diagnosis and treatment of
Alzheimer’s disease
David J. Hayne, SinChun Lim and Paul S. Donnelly*
Alzheimer’s disease is the most common form of age-related neurodegenerative dementia. The disease is
characterised by the presence of plaques in the cerebral cortex. The major constituent of these plaques is
aggregated amyloid-b peptide. This review focuses on the molecular aspects of metal complexes
designed to bind to amyloid-b. The development of radioactive metal-based complexes of copper and
technetium designed as diagnostic imaging agents to detect amyloid burden in the brain is discussed.
Separate sections of the review discuss the use of luminescent metal complexes to act as non-
conventional probes of amyloid formation and recent research into the use of metal complexes as
inhibitors of amyloid formation and toxicity.
1 Brief introduction to the pathology
of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative
condition that results in synaptic failure and neuronal death.
These symptoms initially manifest as mild forgetfulness but
lead to complete loss of cognition.1 Characteristic pathological
hallmarks in the brains of those suﬀering with the disease
include the presence of extracellular senile plaques, intracellular
neurofibrillary tangles and altered levels of neurotransmitters.
Amyloid plaques are composed of an insoluble aggregated
peptide called amyloid-b (Ab).2,3 This peptide is 39–43 residues
in length and derived from the amyloid-b precursor protein (APP).
The amyloid plaque burden in subjects does not consistently
correlate with cognitive impairment and some argue that smaller
soluble oligomeric species are the toxic species responsible for
neuronal death.4–8 However, oligomers and plaques are thought
to be in equilibrium. Although the exact role of amyloid plaques
in the onset of dementia is controversial, what is certain is that
histopathological studies show extensive cortical Ab deposition in
post-mortem analysis of AD subjects.1 Neurofibrillary Tangles
(NFT) consist of a hyper phosphorylated form of a microtubule-
associated protein called tau. NFT initiate with the formation of
bundles of paired helical filaments that accumulate in the
neuronal cytoplasm. The hyper-phosphorylation of tau results
in its detachment from microtubules that consequently lose
structural integrity with concomitant impaired axonal transport
and compromised synaptic function.9 Another prominent
and consistent feature of AD is deficits to the acetylcholine
(cholinergic) neurotransmitter system. Post-mortem studies have
revealed cholinergic neuronal loss and reduced acetylcholine
levels. This correlates with a decrease in the concentration of
acetylcholine esterase, an enzyme responsible for the hydrolysis
of acetylcholine in the brain.10
The focus of this review is metal complexes designed to bind
to either Ab fibrils or Ab plaques as distinct from metal-binding
‘‘free’’ ligands designed to displace either copper or zinc or iron
ions that are thought to be bound to Ab plaques. The approaches
that are discussed in this review include: the potential of radio-
active copper and technetium complexes to be used as diagnostic
imaging agents to elucidate plaque burden in living patients; the
use of luminescent metal complexes as non-conventional probes
of amyloid formation; and the use of platinum, ruthenium,
iridium and rhodiummetal complexes to inhibit the aggregation
and toxicity of Ab. Several elegant and sophisticated approaches
that use chelating ligands designed to attenuate CuII/ZnII–Ab
interactions and redistribute metal ions bound to Ab plaques
that are of significant interest as potential therapeutics will not
be discussed in this review but selected leading references11–26
and reviews27–32 are available.
2 The amyloid-b peptide and plaques
The amyloid precursor protein (APP) is encoded by a single gene
on chromosome 21 and resembles a cell-surface receptor having a
single transmembrane domain, a large extracellular domain and a
short cytoplasmic tail. The transmembrane domain extends
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into the intracellular region and contains the C terminus while
the N terminus resides within the extracellular domain.30 Two
pathways exist for the processing of APP, one being non-
amyloidogenic whilst the other pathway is amyloidogenic
(Fig. 1). Non-amyloidogenic metabolism involves cleavage of
APP by a-secretase, a membrane anchored secretase, releasing
the soluble N terminus fragment, sAPPa, to the extracellular
space. The remaining transmembrane fragment is cleaved by
g-secretase within the transmembrane domain liberating non-
amyloidogenic P3 (Ab17–40 or Ab17–42) to the extracellular space.
The amyloidogenic proteolysis of APP follows a similar series of
events but is cleavage with b-secretase (also known as b-APP
cleaving enzyme or BACE-1) followed by g-secretase releases
sAPPb and Ab. Ab ranges in length from 39–43 amino acids
depending where g-secretase cleavage occurs giving variability at
the hydrophobic C-termini connected to the hydrophilic N-terminal
domain.33 The two main peptides produced are 40 (Ab40) and 42
(Ab42) amino acid residues in length; Ab42 shows the greater
propensity for aggregation in vivo and is often considered the
more toxic.34,35 As monomers, the peptides show unfolded random
coil conformation with some a-helical and b-sheet structure. An
imbalance between the production and clearance of Ab peptide
results in its accumulation as oligomers, protofibrils, fibrils, and
then extracellular Ab plaque deposits in the brain parenchyma.
The amyloid hypothesis argues that Ab plaques and/or their
precursors trigger a cascade of events leading to synaptic
dysfunction, microgliosis, and neuronal loss.1,36,37
Amyloid is a general term used to describe peptides or
proteins that form b-sheets which accumulate as highly ordered
fibrillar aggregates.40 One of the earliest methods to identify
amyloids was the apple green birefringence histological dye
Congo Red (Fig. 5) displayed once bound to amyloid when
observed under polarized light leading to the first definition
criterion of amyloid.41–43 The second definition criterion for
amyloid is to possess fibrillar morphology.43,44 Negatively stained
thin tissue sections containing amyloid imaged with electron
microscopy (EM) reveal bundles of straight, rigid fibrils. Mature
amyloid fibrils are estimated to be about 75–100 Å in width.
Assembly involves two to four thin protofilaments twisting
together parallel to the fibril axis. An individual protofilament
consists of several b-sheets composed of peptide chains bound
together by hydrogen bonds. The b-strands (monomeric Ab) are
aligned perpendicular to the fibril axis (cross-b structure)
(Fig. 2).45,46 Electron microscopy and X-ray diffraction analysis
of the Ab protofilament reveals the inter-peptide chain spacing
to be about 4.8 Å and inter-sheet spacing to be about 10 Å,
characteristic of the cross-b structure.42,47,48
Amyloid fibrils are not crystalline and generally insoluble in
aqueous solvents. This precludes analysis by conventional
solution NMR. Nevertheless, recent advances in cryoelectron
microscopy and solid-state NMR have provided structural
information on the inter- and intra-molecular interactions that
bind the cross-b structural motifs of Ab fibrils.45,48–53 Structural
studies using fibrils formed from 35MoxAb42 peptides (containing
a methionine sulfoxide at position 35) have given insight into the
3D structure of Ab42 fibrils (Fig. 3). The methionine is oxidised
during the production of the monomeric peptide but maintains
similar properties to the non-oxidised Ab42.
54 A single 35MoxAb42
protofilament consists of two b-sheets (b1 and b2) that run along
the fibril axis forming a parallel b-sandwich stabilized by inter-b-
sheet side-chain interactions. Residues 17–26 define sheet b1
and residues 31–42 form sheet b2 with a connecting loop
containing residues 27–30. Intermolecular interactions between
amino acid residues on b1- and b2-sheets involve ionic interac-
tions (Asp23 and Lys28), hydrophobic interactions (Leu17,
Phe19, Ala21, Gly38 and Val36) and backbone hydrogen bonds.
The loop region and b1 interact by salt bridge formation between
Fig. 1 (a) Schematic representation of the non-amyloidogenic (a-secretase
cleavage) and amyloidogenic (b-secretase cleavage) proteolytic pathways of
APP. The specific enzyme cleavage sites on the peptide sequences are as
shown by the black arrows.38,39 (b) TEM image of Ab42 fibrils negatively stained
with uranyl acetate. (c) A section of AD aﬀected human brain tissue treatedwith
an Ab antibody, 1E8, showing extensive Ab plaque deposition.
Fig. 2 Schematic representation of amyloid fibril. (a) b-Strands are arranged
perpendicular to the fibril axis (axis shown in red, side-chains shown as
spheres). (b) Two sheets are paired by the interlocking of side-chains, the two
lighter coloured peptides in each sheet highlight this and correspond with the
lighter coloured peptides in (a). (c) b-Sheets twist together to form a
protofibril which aggregates to form the mature fibril (d) (direction of fibril
axis shown with red arrow). Reproduced with permission from K. K. Skeby,
J. Soerensen and B. Schioett, J. Am. Chem. Soc., 2013, 135, 15114. Copyright
2013 American Chemical Society.
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the side-chains of residues Asp23 and Lys28. Residue Lys28 also
forms close contacts with residues Ile32 and Leu34 of b2. The
intermolecular hydrophobic interaction formed between the
odd-numbered residues of the b1-strands (Leu17, Phe19 and
Ala21) and the even-numbered residues (Gly38 and Val36) of
neighbouring b2-strands establishes the hydrophobic core of
Ab42 fibrils. The extension and growth of the Ab42 protofilament
is unidirectional; an incoming nth Ab42 monomer can initiate
contact with the fibrillar end by means of hydrophobic inter-
actions between its b1-strand and the b2-strand of the (n  1)th
monomer. The ionic interactions between the residues in
the loop regions and backbone hydrogen bonds further
strengthen the intermolecular association. In order to prevent
the dissociation of the nth monomer, another Ab42 monomer is
required to interact with the b2-strand of the nth monomer to
stabilize it. This suggests that the sequence-selective and
cooperative mechanism of Ab42 fibril growth is a first-order
kinetic process.46
3 Structural morphology of amyloid
plaques
The relationship between soluble Ab monomers, oligomers Ab,
protofibrils, fibrils and plaques is complicated and several
aspects of the dynamics remain uncertain.55,56 Amyloid-b plaques
are classified into two morphological types: (i) neuritic and (ii)
diﬀuse (‘‘pre-amyloid’’) plaques (Fig. 4). Neuritic plaques,
observed after staining, have a dense compact spherical appear-
ance with a diameter ranging from 10 mm to greater than 120 mm.
Neuritic plaques can be further sub-classified into ‘fibrillar’
or ‘dense-cored’ plaque forms. Fibrillar plaques show dense
accumulations of Ab throughout the plaque structure (Fig. 4B)
whereas cored plaques have a distinct central core of Ab encircled
by a void or clearing surrounded by an outer spherical rim of Ab
(Fig. 4A). These Ab deposits are referred to as neuritic plaques
as they are spatially localized with dystrophic neuritis (clusters
of abnormal neuronal processes) both inside and immediately
surrounding the deposits.57–59
Following staining, diﬀuse plaques display a finely granular
pattern of amorphous shape that lacks a fibrillar, compacted
centre (Fig. 4C). These non-fibrillar plaques are the only Ab
deposits found in regions of the brain not clearly associated
with the typical symptoms of AD. They also form within the
same regions of the brain as neuritic plaques, however, very
little or no detectable dystrophic neurites are associated with
Fig. 3 (a and b) Ribbon diagrams of the protofibril core structure
(residues 17–42) illustrating the intermolecular nature of the b-strand
interactions. Ab monomers are individually colored. The b-strands are
indicated by arrows, non-regular secondary structure is indicated by spline
curves through the Ca atom coordinates of the corresponding residues.
The bonds of side chains that constitute the core of the protofilament are
shown. (b) Dotted lines indicate ion pair interactions forming intermole-
cular salt bridges between residues D23 and K28, two salt bridges formed
by the central Ab42 molecule are highlighted by rectangles. (c) Van der
Waals contact surface polarity with a ribbon diagram at the odd end of the
35MoxAb42 protofilament showing residues 17–42. The colours of side
chains indicate if they are hydrophobic (yellow), polar (green), negatively
charged (red), or positively charged (blue). Positively and negatively
charged surface patches are shown in blue and red, respectively, and all
others are shown in white. (d) (upper) Simulation of a 35MoxAb42 fibril that
consists of four protofilaments colored individually. Lower shows the same
fibril in a noisy gray-scale image, which has been blurred corresponding to
a resolution of 2 nm. In right, a 5-magnified cross section perpendicular
to the fibril axis is shown, using the same color code. Dimensions are
indicated. To match the experimental twist of the protofilament of the fibril
shown in (e), a twist angle of 0.451 per molecule was used. (e) Two
examples of cryoelectron micrographs of single 35MoxAb42 fibrils. The
direction of the fibril axis is indicated by the direction of the black arrows
(scale bar, 50 nm). Adapted with permission from T. Luhrs, C. Ritter,
M. Adrian, D. Riek-Loher, B. Bohrmann, H. Dobeli, D. Schubert and R. Riek,
Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 17342. Copyright 2005 National
Academy of Sciences, U. S. A.
Fig. 4 Serial sections of human brain tissue displaying Ab plaques of
diﬀerent morphologies. (A, i–iii) Optical sections of a dense core plaque,
observed after staining with a histological dye for amyloid. Images were
captured atB14.5 mm intervals and show the dense Ab core of the plaque
(arrow) (A, ii) surrounded by a void defined by an outer rim of Ab (arrow
heads). (B, i–iii) Similar images of a fibrillar plaque with images captured at
intervals of B17.5 mm. Spoke-like Ab accumulations (arrow) radiate from
the dense central accumulation. (C, i–iii) Confocal images of a diffuse
plaque after treatment with an Ab antibody. The images were captured at
intervals of B2.5 mm and show the punctate accumulation of Ab giving a
granular pattern. Scale bar = 20 mm (A and B), 50 mm (C). Reproduced with
permission from T. C. Dickson and J. C. Vickers, Neuroscience, 2001, 105,
99–107. Copyright 2001 Elsevier.
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
M
ar
ch
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
9/
08
/2
01
7 
04
:3
5:
01
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
6704 | Chem. Soc. Rev., 2014, 43, 6701--6715 This journal is©The Royal Society of Chemistry 2014
diﬀuse plaques. Studies in a transgenic ADmousemodel, expressing
mutant human APP, show that the mice develop diﬀuse plaques
before fibrillar plaques supporting the hypothesis that diﬀuse
plaques are immature or precursor lesions to neuritic plaques
and are therefore also termed ‘‘pre-amyloid’’ plaques.57
4 Molecules that bind to Ab fibrils and
plaques
The histopathological dyes Congo Red and Thioflavin T (ThT)
(Fig. 5) have provided the structural inspiration for the development
of many radiolabeled tracers aimed at detection of amyloid in living
patients. Both dyes are relatively planar, hydrophobic aromatic
molecules that interact with and bind to the cross-b sheet structure
found in all amyloid fibrils. They are unable to cross the blood–brain
barrier at least in part due to their ionic charge.
Over the last decade there has been significant progress in the
development of positron emission tomography (PET) imaging
agents to characterise Ab plaque burden. PET is a non-invasive
molecular imaging technique that relies on the detection of
radioactivity emitted from a positron-emitting isotope that is
incorporated into a molecular tracer or imaging agent. The emitted
positron annihilates releasing two gamma photons travelling in
opposite directions. Detection of the emitted photons allows the
generation of an image with a spatial resolution of 3–5 mm with
high sensitivity. An analogue of ThT, the 2-phenylbenzothiazole
derivative 2-(4(methylamino)phenyl)benzothiazol-6-ol (11C-PiB)
(Fig. 6), contains the positron emitting isotope carbon-11, is
able to cross the blood brain barrier, and labels Ab plaques
in vivo. It has been used in pioneering clinical studies that have
demonstrated the tremendous potential of PET imaging in
assisting AD diagnosis.60 The longer half-life of fluorine-18 when
compared to carbon-11 is more practical and fluorine-18 is
currently the most widely used radionuclide for PET imaging.
Benzothiazole derivatives and an aromatic fluoro-substituted
pyridinyl benzofuran radiolabeled with fluorine-18 are in the
late stages of clinical development. The pyridinyl benzofuran
compound, AZD4694 (Fig. 6), has completed phase III clinical
trials and compares favourably to PiB displaying relatively low
non-specific binding when compared to other 18F radiotracers.61
Flutemetamol (Fig. 6), a benzothiazole derivative, has recently gained
FDA approval to estimate beta amyloid neuritic plaque density.62
Another pharmacophore that has shown considerable potential
in binding to Ab plaques contain diaryl alkenes such as stilbenes
and styrylpyridines. The development of the 18F labelled stilbenes
and styrylpyridines is presented in a ‘perspective’ article63 and
the research in this area has led to the recent FDA approval of
18F-AV45 (florbetapir) (Fig. 6) to detect the presence of amyloid.64
The use of the benzothiazole dye ThT as a fluorescent probe
for the detection of amyloid-like structures was first reported in
1959.65 In protic solvents ThT absorbs at a wavelength of
340 nm with a relatively weak emission at 445 nm but when
bound to amyloid fibrils the dye undergoes a 115 nm red shift
in excitation profile (lex = 445 nm) with enhanced emission at a
wavelength of 485 nm. In aqueous solutions rapid rotation
about the C–C bond linking the benzothiazole group to the
N,N-dimethylaniline portion of the molecule provides a pathway
for non-emissive decay of the excited state. This occurs by a
twisted internal charged-transfer process (TICT) from a locally
excited state (LE) by increasing the torsion angle from 371 to 901.
The interaction of ThT with amyloid fibrils restricts rotation
about the C–C bond and is partially responsible for the increased
emission (Fig. 7).66–70 It is likely that there are three different
binding sites for ThT on Ab40/42 fibrils.
71,72 The first and second
binding sites (BS1 and BS2) have higher binding affinities
than the third (BS3) and are located closely and/or overlapping
to each other. BS1 occurs every B35 Ab40 monomers while BS2
occurs every B4 Ab40 monomers and low capacity BS3 occurs
everyB300 Ab40 monomers.
72 Hydrophobic grooves are formed on
the b-sheet surface by the side-chains of amino acids, particularly
Phe and Val. These hydrophobic grooves propagate along the
‘‘twisting’’ Ab fibril forming BS1 and BS2. Interaction of ThT with
the side-chains of these grooves is thought to be primarily via p–p
stacking. The low affinity and less abundant BS3 is present on the
b-sheet extremities of the fibril.73
Simulated molecular dynamics support the proposed groove
binding of histological dyes and small-molecule imaging agents
to amyloid. The Asp-Phe-Gly-Ala-Ile-Leu-Ser peptide sequence,
found within human islet amyloid polypeptide, acts as a useful
model for binding simulations of small molecule imaging agents
and dyes, including ThT and the related radiotracer 11C-PiB. The
simulated fibril construct consists of a double layer of b-sheets,
each containing 10 in-register antiparallel b-strands. The aminoFig. 5 The structure of the histological dyes, Congo Red and Thioflavin T.
Fig. 6 Structures of AZD4694, PiB, flutemetamol, and florbetapir.
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acid side chains decorate the large faces of the fibril to form
grooves on both faces (Fig. 8a).
The top face of the fibril has a central groove consisting of
isoleucine residues and two neighbouring minor grooves formed
with isoleucine on one side and alternating arginine and serine
residues on the other. Although the bottom face of the fibril has
potential for two grooves, phenylalanine residues leaning toward
the alanine residues restrict access to one groove but the small
alanine residues allow room for a single small hydrophobic
central groove. Amongst the multiple potential binding sites
available, the two binding modes with the highest binding
aﬃnities are in the hydrophobic grooves of the top and bottom
faces. The absolute energetic contributions of binding can be
classified as polar or non-polar. The non-polar interactions
provided the largest contributions to the interactions and a
major proportion can be speculatively assigned to p–p interac-
tions. Comparison of the charged ThT and its neutral analogue
PiB reveals greater insertion into the hydrophobic grooves for
PiB corresponding to a more energetically favourable binding to
the fibril (Fig. 8b and c). It is reasonable to expect this to
translate to fibrils formed with other peptides, such as Ab, due
to the similarity across amyloid fibril structure.55
5 Toward diagnostic imaging of
Alzheimer’s disease with copper
radiopharmaceuticals
The positron-emitting isotopes of copper oﬀer considerable
potential for diagnostic PET imaging.74,75 There are two com-
paratively short-lived isotopes, copper-60 (t1/2 = 20 min) which
is relatively easy to produce with a small medical cyclotron and
copper-62 (t1/2 = 20 min), available from a convenient generator.
Two longer half-life isotopes, copper-61 (t1/2 = 3.4 h) and
copper-64 (t1/2 = 12.7 h) can both be produced in low energy
hospital cyclotrons.74 The low energy of the positron-emission
from copper-64 is coupled to a lack of interfering gamma
emissions so high quality images are obtained that are compar-
able to those obtained with fluorine-18.76 In principle, the rapid
and simple incorporation of a radioactive copper isotope into a
specifically designed targeting ligand is an attractive alternative to
the sometimes challenging covalent incorporation of carbon-11 or
fluorine-18 into plaque binding tracers. Such a system needs to
be carefully designed as factors such as complexation kinetics,
thermodynamic stability and biodistribution need to be con-
sidered. A single ligand framework is suitable for the full range
of copper isotopes and would serve as a valuable platform to
develop versatile Ab plaque imaging agents and improve the
Fig. 7 Photophysical properties of ThT. (a) The two planar groups within
ThT rotate about the C–C bond with an angle of torsion, c. (b) Fluores-
cence emission of ThT (red) and ThT with Ab42 in phosphate buffer (lex =
444 nm). M. Biancalana and S. Koide, Biochim. Biophys. Acta, Proteins
Proteomics, 2010, 1804, 1405–1412. Copyright 2010 Elsevier.
Fig. 8 (a) Surface representation of the top face and bottom face of the
simulated Asp-Phe-Gly-Ala-Ile-Leu-Ser fibril construct, blue arrows show
three grooves on the top face and single groove on the bottom face
with red arrows showing the direction of the fibril axis. Representative
structures for ThT (b) and PiB (c) clusters are coloured by their free
energies of binding to the simulated fibril. A large binding free energy
value represents a favourable contribution to binding energy. Clusters
are defined by the positions of heavy atoms within the compound with
respect to the Ca atoms of the fibril, the representative is chosen as
the structure with the lowest RMSD to the average structure of each
respective cluster. Adapted with permission from K. K. Skeby, J. Soerensen
and B. Schioett, J. Am. Chem. Soc., 2013, 135, 15114. Copyright 2013
American Chemical Society.
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number of clinical centers that are capable of assessing Ab
plaque burden in patients.
A family of ligands known as bis(thiosemicarbazones) (btsc),
derived from 1,2-diones, can be used as delivery vehicles
for radioactive copper isotopes as they form stable (Ka = 10
18)
and neutral membrane permeable copper complexes.77–81 The
copper complex [64CuII(atsm)] (Fig. 9) is currently undergoing
clinical trials in humans for imaging hypoxia in head and neck
cancers.82–85 It is thought that the hypoxia selectivity of the
complex involves the metal ion being reduced from CuII to CuI.
The copper(II) bis(thiosemicarbazonato) complex with a single
methyl substituent on the backbone of the ligand, [CuII(ptsm)]
(Fig. 9), has been used to image blood perfusion in humans and
over 5% of the injected dose reaches the brain highlighting its
ability to cross the blood brain barrier.86,87
[CuII(atsm)] is also able cross the blood–brain barrier and
the uptake of radiolabeled [CuII(atsm)] in the brain has been
used to probe cellular redox status in the brains of patients with
mitochondrial myopathy, encephalopathy, lactic acidosis and
stroke-like episodes (MELAS) and to evaluate striatal oxidative
stress in patients with Parkinson’s disease. The CuII/CuI redox
potential of [CuII(btsc)] complexes is dependent on the substitu-
ents on the diimine-like backbone of the ligand. For example,
the CuII/CuI reduction potential in [CuII(atsm)] is about 160 mV
more negative than the complex with two hydrogen atoms on
the backbone, [CuII(gtsm)]. This difference in redox chemistry
has been used to investigate differences in copper metabolism
in a mouse model of amyloid pathology. The Ab42 peptide binds
copper and amyloid plaques have elevated levels of copper
(as well as zinc and iron) and it has been suggested that the
transmembrane amyloid precursor protein may play a role in
the control of nutrient copper. Both [64CuII(atsm)] and
[64CuII(gtsm)] cross the blood–brain barrier but the brain
uptake of [64CuII(gtsm)] in APP/PS1 model of amyloid pathology
mice is higher than [64CuII(atsm)]. The uptake of [64CuII(gtsm)]
in the brain (expressed as % of the injected dose per gram
(body weight), %ID per g) is significantly higher ( p = 0.01)
in APP/PS1 mice when compared to control animals (3.0 
0.25% ID per g in the APP/PS1 mice compared to 1.58  0.14%
ID per g in wild type control animals). This difference is
presumably a result of changes to copper metabolism and is
not a measure of plaque burden.81 The ability to alter both
the CuII/CuI reduction potential and the biodistribution of
[CuII(btsc)] complexes by altering the substituents on the ligand
means they have potential to investigate both redox status and
altered coppermetabolism in other neurological conditions such
as Wilson’s and Menkes disease. The potential of [CuII(gtsm)]
and related complexes to probe molecular changes in Alzhei-
mer’s disease and other neurological diseases warrants more
detailed investigations.
As [CuII(atsm)] has suﬃcient stability for brain imaging it
appeared to be a useful starting framework to develop bifunctional
chelates with the potential to be used as Ab plaque imaging agents.
The CuII/CuI reduction potential in [CuII(atsm)] is such that it
is thought, at least to some extent, reduction is only likely to
occur intracellularly in hypoxic cells so reduction to CuI would
not be expected when targeting extracellular Ab plaques. A new
bis(thiosemicarbazone) ligand with an appended plaque targeting
trans-stilbene functional group, H2L
1 was prepared by a condensa-
tion reaction between trans-stilbene aldehyde and the bifunctional
chelate atsm/a (Fig. 9). The copper complex, [CuIIL1], interacts with
synthetic Ab42 fibrils in vitro and binds selectively to Ab plaques in
post-mortem samples of human brains from AD subjects (Fig. 10).
The binding of [CuIIL1] to Ab plaques was demonstrated in
serial sections (7 mm) of frontal cortex tissue treated with a
solution of [CuIIL1]. The complex is fluorescent due to the
presence of the stilbene functional group allowing examination
by epifluorescence microscopy and comparison to the contig-
uous section that was immuno-stained with an Ab antibody
(1E8) to identify plaques. Ab plaques are typically 40–60 mm in
diameter, indicating that 7 mm serial sections would comprise
the same Ab plaques. The [64CuL1] complex crosses the blood–
brain barrier and displays increased uptake in the APP/PS1
model of amyloid pathology when compared to age-matched
control animals. The brain uptake was significantly higher
( p = 0.005) in the APP/PS1 transgenic mice when compared
with wild-type (2.5%  0.6 compared to 1.7%  0.6, %ID per g)
at 7 minutes after the injection.88
Fig. 9 Structures of bis(thiosemicarbazonato) copper(II) complexes.
Fig. 10 Serial sections of human brain tissue from AD aﬀected subjects.
(a) Sample immuno-stained with 1E8 antibody and (b) sample treated with
[CuIIL1].
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
M
ar
ch
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
9/
08
/2
01
7 
04
:3
5:
01
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2014 Chem. Soc. Rev., 2014, 43, 6701--6715 | 6707
To reduce the size and molecular weight of the ligand hybrid
thiosemicarbazone–benzothiazole and thiosemicarbazone–
styrylpyridine tetradentate ligands H2L
2–4 were prepared. All
three ligands form stable complexes with CuII and the mono-
cations [CuIIHL2]+ and [CuIIHL3]+, where the hydrazine limb of
the ligand remains protonated, were characterised by single
crystal X-ray crystallography (Fig. 11b). In the solid state the
CuII is 5-coordinate square pyramidal with the ligand acting as
a quadridentate N3S donor and weaker axial interactions with the
sulfur atom from an adjacent molecule to give a dimer. Electronic
spectroscopy showed that all the complexes were charge-neutral
in aqueous buffer at pH 7.4. The ligands form stable complexes
with CuII and for [CuIIL4] the conditional dissociation constant
(KD) is 5.8(4) 1018 M at pH 7.4. The CuII complexes that feature
the styrylpyridine functional group, [CuIIL3] and [CuIIL4], have a
quasi reversible reduction at about0.68 V (vs. SCE) attributed to
a CuII/CuI couple, 80 mV more negative the CuII/CuI couple for
[CuII(atsm)]. The complexes [CuIIL3–4] bind to Ab plaques in AD
affected human brain tissue, with plaques identified by staining
the contiguous section with 1E8 antibody (Fig. 11c), even though
the pyridyl nitrogen atom within the styrylpyridine is coordinated
to CuII. Both H2L
3 and H2L
4 formed complexes with copper-64 at
room temperature, [64CuIIL3] and [64CuIIL4], and the distribution
coefficients (logD) values of 1.90 and 1.87 are comparable to
[CuII(atsm)] (1.85). The brain uptake of [64CuIIL3] was investigated
by micro-PET imaging in wild-type mice and revealed essentially no
radioactivity evident in the brain five minutes post injection. The
images obtained following administration of [64CuIIL4] were more
promising with significant radioactivity observable in the brain. A
separate biodistribution study that revealed that, at five minutes
post injection, 1.11 (0.20) %ID per g of [CuIIL4] had accumulated in
the brain, and in wild-type mice without Ab plaques, the radio-
activity cleared to 0.38 (0.09) %ID per g 30 min post injection. The
addition of a –(CH2)2N(CH3)2 functional group to form [Cu
IIL4]
increases the molecular weight and has little effect on the logD
but increases the ability to cross the blood–brain barrier when
compared to [CuIIL3]. This functional group is capable of
forming an intramolecular hydrogen bond and may alter the
solvation properties of the complex thus modifying membrane
permeability. It is also possible that this functional group
produces other complicating interactions such as those with
serum proteins or the p-glycoprotein efflux system. Further
studies on these systems are warranted including investigation
in transgenic models of amyloid and more detailed character-
isation of their biodistribution and metabolism.89
Specifically designed ligands to probe Ab plaque burden such as
the systems presented above could be incorporated into ‘kit’
formulations in a similar manner to successful technetium-99m
based radiopharmaceuticals. In principle, these ligands would be
for suitable each of the positron-emitting isotopes of copper
oﬀering incredible versatility and flexibility from a single platform.
6 Technetium-99m radiotracers
designed to bind to amyloid-b
Although the use of the imaging technique single photon
emission computed tomography (SPECT) is routine and wide-
spread, progress toward a SPECT compatible molecular probe
has been slower than that of PET.90 The most commonly used
radioisotope for SPECT imaging is technetium-99m. This g-emitting
isotope has a half-life of six hours and is available from convenient
generator systems. A 99mTc-based radiotracer for determining plaque
burden would be of considerable clinical utility and increase the
number of centres that are able to perform diagnostic scans for AD
based on both cost and availability of the necessary infrastructure.
As there are no non-radioactive isotopes of technetium, it is
common practice to use the relatively stable isotopes of rhenium
to form analogues of 99mTc complexes for comprehensive char-
acterisation and preliminary in vitro assessment.90–92 Detailed
reviews on the chemistry of technetium are available93–95 and
earlier detailed reviews on diagnostic imaging of AD with 99mTc
complexes were published in 2011 and early 2012 (see Fig. 12 for
selected examples).90,92 The significant progress towards a 99mTc
complex for Ab plaque imaging published in articles from 2012
onwards are highlighted in the following section.
A N2S2 donor often forms neutral complexes with the
[MVO]3+ (M = Re or Tc) core, particularly the ligands derived
from bis(aminoethanethiol) (BAT) and monoamine–monoamide
dithiol (MAMA). A comparison between [TcOBAT] and [TcOMAMA]
complexes tethered to a phenylbenzoxazole plaque targeting
Fig. 11 (a) Structure of complexes [CuL2], [CuL3], and [CuL4]. (b) ORTEP
(ellipsoids at 40% probability) representations of [CuII(HL2)]2(BF4)24DMF
and [CuII(H2L
3)]BF42DMF with solvent molecules and anions omitted for
clarity. The dication dimer, [CuII(HL2)]2(BF4)24DMF contains benzothiazole
rings that are disordered over 2 sites (occupancy 0.5). (c) AD human brain
sections (20 magnification) with 1E8 antibody stain and (d) epi-
fluoresence microscopy of CuL4 binding to Ab plagues.
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group revealed that the [TcOBAT] complexes displayed higher
brain uptake.96 Amino, monomethylamino, or dimethylamino
substituted pyridyl benzofuran functional groups have also
been used as the basis for targeted binding of Ab plaques in
a bifunctional chelate formed by N-alkylation of BAT (Fig. 13).97
Tetradentate N2S2 ligands with N-alkylation of the ligand leads
to the possibility for syn and anti isomers with respect to the
position of the pendant group in relation to the apical oxo
ligand. However, in the case of H3L
5–7 a single radioactive peak was
observed by radio-high performance liquid chromatography upon
radiolabeling with 99mTc. The octanol water partition coefficient (P)
is used to give an indication of the biodistribution of compounds.
LogP values were 0.68, 1.35, and 2.09 for [99mTcOL5–7] respectively.
Brain uptake in ‘normal’ mice 2 min post injection was 1.59 (0.21)
%ID per g and 1.80 (0.16) %ID per g for [99mTcOL5] and [99mTcOL6]
respectively while [99mTcOL7] has a brain uptake of 1.64 (0.27) %ID
per g at 10 min with all three showing good clearance from the
brain. The highest brain uptake was shown by [99mTcOL6] (1.80%
ID per g) but, of the rhenium analogues, [ReOL7] displayed the
highest binding affinity toward Ab42 aggregates in vitro (Ki 13.6 nM).
The compound that displayed the highest uptake in the brain,
[99mTcOL6], was evaluated in Tg2576 mice which display high
Ab plaque deposition in the brain. The murine brain samples
examined by ex vivo autoradiography demonstrated that the
tracer accumulated in the same deposits as Thioflavin S.97
In an alternative approach a dibenzylideneacetone derivative,
containing a dimethylamino group, was conjugated to both BAT
and MAMA (Fig. 14). Once again, rhenium complexes were used
as non-radioactive surrogates to assess the binding aﬃnity of
complexes toward aggregated Ab. The binding aﬃnities of
MAMA rhenium complexes, [ReOL8–9], to Ab42 aggregates were
moderate (Ki = 121 and 60 nm for [ReOL
8–9] respectively)
increasing to high aﬃnity for BAT rhenium complexes (Ki = 25
and 14 nm for [ReOL10–11] respectively). All complexes, [ReOL8–11],
bind in vitro to Ab plaques within brain samples from transgenic
model mice (APP/PS1). Complexes [99mTcOL9–11] display relatively
high lipophilicity, with logD values ranging from, 3.17 to 3.53.
Brain uptake of the complexes in wild-type mice is relatively low
with no significant diﬀerence between BAT containing complexes,
[99mTcOL8–9], and the MAMA containing complex [99mTcOL10],
having an uptake ranging from 0.47 to 0.49% ID per g 2 min post
injection. An even lower brain uptake of 0.31% ID per g 2min post
injection was observed for [99mTcOL11]. Compounds [99mTcOL8–10]
cleared the brain over time (brain2min/brain60min = 6.13, 3.92 and
5.33 for [99mTcOL8–10] respectively) while a significant amount
of activity was recorded in the brain 60 min post injection for
[99mTcOL11] (brain2min/brain60min = 2). The brain clearance is
important for radiotracers as fast brain clearance is necessary
to remove unbound radiotracer, giving a high signal to noise
ratio aﬀording clear images.98
An integrated approach similar to the tetradentate hybrid
thiosemicarbazone–styrylpyridine systems ([CuL3] and [CuL4]),
whereby the binding motif forms part of the chelate backbone,
reduces the molecular weight of compounds and potentially aid
blood–brain barrier permeability. Examples of such ligands have
been synthesised incorporating 2-arylbenzothiazole (2-ABT) deriva-
tives as the targeting motif (Fig. 15). The binding affinity of
rhenium complexes, [ReOL12–19], was assessed according to their
binding affinity to Ab40 fibrils and logPC18 (PC18 = estimation of P by
a reverse phase HPLC method). This revealed that both the type of
chelator and substitution positions about 2-ABT (see Fig. 15 ThT for
numbering) influences the affinity of complexes toward Ab fibrils.
Fig. 12 Selected examples of technetium complexes designed to bind to
Ab plaques. For recent reviews see ref. 90 and 92.
Fig. 13 General structure of complexes (represented in text as MOLx)
containing BAT chelate conjugated to pyridyl benzofuran derived Ab
binding group; where M = ReV or 99mTcV; L5, R = NH2; L
6, R = NHMe;
L7, R = NMe2.
Fig. 14 General structure of complexes containing MAMA and BAT ligands
conjugated to dibenzylideneacetone derived Ab binding group; M = ReV or
99mTcV; L8, n = 2; L9, n = 4; L10, n = 2; L11, n = 4.
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Addition of an electron donating group or halogen to 2-ABT at
6- or 40-positions, in general, increases binding affinity of these
complexes toward Ab40 fibrils as does incorporating 2-ABT into
the ligand chelator via its phenyl ring. The two rhenium complexes
that show the most promise of this set of compounds are [ReOL15]
(R = OMe) and ReL18 (R = F). Both contain semi-rigid chelates that
integrate the 2-ABT group through the phenyl ring with the amino
group at the 40-position. Although the binding affinities of these
complexes (Ki B 30 nM) is inferior to that of most clinical Ab
imaging agents (o10 nM) the integrated approach using other Ab
binding motifs may prove more successful.99
The low valent oxidation state of technetium(I) can be
stabilized by carbonyl ligands. Pioneering method development
has led to the synthesis of fac-[99mTcI(CO)3(H2O)3]
+ from
[99mTcVIIO4]
 using sodium boranocarbonate as both reducing
agent and an in situ source of carbon monoxide allowing for the
convenience of a kit formulation.100–102 These low spin d6 systems
offer high kinetic stability. The stable M–C bonds favour exchange
of the water ligands allowing the introduction of mono-, bi- or
tridentate ligands and the possibility for [2+1] mixed ligand
complexes by coordination of both a mono and bidentate ligand
in the one complex.
A benzothiazole pendant group conjugated to a picolylamine
monoacetate chelate ligand coordinates in a tridentate manner
with [MI(CO)3]
+ (M = Re or 99mTc) to give stable, neutral complexes
[M(CO)3L
20] (Fig. 16). Human brain tissue, collected from subjects
diagnosed with AD, when treated with [Re(CO)3L
20] shows binding
of the complex to Ab plaques. Similarly, [99Tc(CO)3L
20] also binds
to Ab plaques but no binding is detected when a shorter acet-
amide linker is used to connect the benzothiazole group with the
chelate. Brain uptake of [99mTc(CO)3L
20] administered through tail
vein injection to Swiss Albino mice showed moderate brain
uptake at 1 minute post injection (0.69% ID per g) combined
with fast clearance (0.05% ID per g 15 min post injection; 0.02%
ID per g 60 min post injection).103
Selected substituted chalcones have a conjugated planar
structure and bind to Ab plaques. Replacement of a phenyl ring
with a cyclopentadienyl functional group allows the synthesis of
‘‘piano stool’’ type complexes [CpM(CO)3] (where Cp = cyclopenta-
dienyl andM = ReI or TcI). Rhenium complexes were synthesised by
acetylation of (cyclopentadienyl)tricarbonylrhenium using acetyl
chloride.91 The product was then reacted via base catalysed Claisen
condensation with the chosen aromatic aldehyde enabling varia-
tion in the length of the alkenyl group within complexes (Fig. 17).
The synthesis of 99mTc analogues, [99mTc(CO)3L
21–23], can be
accomplished by a two-step process: first, [CH3COCp
99mTc(CO)3]
is synthesised from pertechnetate by a double ligand transfer
(DLT) using acetylferrocene and [Mn(CO)5Br]; the resultant
complex is then reacted via a base catalysed Claisen condensa-
tion with the selected aromatic aldehydes to aﬀord complexes in
approximately 25% radiochemical yield over the two steps.
The rhenium surrogates, [Re(CO)3L
21–23], showmoderate binding
aﬃnities toward Ab42 aggregates. Binding aﬃnity towards Ab42
improves with increasing length of the alkenyl group to be at a
maximum for [Re(CO)3L
23] (Ki = 108 16 nM). This trend is repeated
for the binding of complexes [99mTc(CO)3L
21–23] to Ab42 aggregates,
however, an inverse relationship between the length of alkenyl chain
and brain uptake in normal ICR mice results in 99mTcL21 showing
the highest uptake at 2 min post injection (4.10  0.38% ID per g)
and good clearance from the brain (brain2min/brain60min = 8.20).
91
A mixed ligand system, whereby bidentate and monodentate
ligands are used to complete the coordination sphere about
Fig. 15 General structure of complexes containing 2-arylbenzothiazoles
for Ab binding; R = H, F, or OMe.
Fig. 16 Structure of ML20 containing benzothiazole based pendant group
conjugated to a tridentate chelate; M = ReI, 99TcI or 99mTcI.
Fig. 17 General structure of complexes containing chalcone inspired
cyclopentadienyl ligand; M = ReI or 99mTcI; L21 n = 1, L22 n = 2, L23 n = 3.
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fac-[M(CO)3]
+ producing a ‘‘2+1’’ system, allows for the possibility of
altering pharmacokinetics without modifying the binding motif.
The a,b-unsaturated b-diketone curcumin (HL24) binds to Ab
plaques and is able to act as a bidentate ligand when reacted with
fac-[M(CO)3(H2O)3]
+ to form fac-[M(CO)3L
24(H2O)] (M = Re or
99mTc). The remaining aqua ligand can be exchanged for imidazole,
isocyanocyclohexane, and triphenylphosphine (Fig. 18).104,105 The
large trans eﬀect exerted by triphenylphosphine can lead to further
substitution and formation of [Re(CO)2(PPh3)2L
24]. The substitution
chemistry is similar for 99mTc. The aqua ligand of the intermediate,
[99mTc(CO)3L
24(H2O)], is replaced by a phosphine ligand at room
temperature to give [99mTc(CO)3L
24(PPh3)] in 80% radiochemical
yield, with 20% remaining as the intermediate complex. When
incubated at 60 1C for 20 min, the reaction progresses to form cis–
trans-[99mTc(CO)2(PPh3)2L
24]. Both fac-[Re(CO)3L
24(PPh3)] and cis–
trans-[Re(CO)2(PPh3)2L
24] bind to Ab plaques in post-mortem
human brain tissue.105
7 The interaction of phosphorescent
ruthenium polypyridyl complexes with
Ab fibrils
Specifically designed phosphorescent metal complexes are an
interesting alternative to conventional organic fluorescent probes
of fibril formation due to their long-lived fluorescent life times
due to the spin–orbit coupling promoted by heavy metal ions.
The ruthenium polypyridyl complex [RuII(bpy)2(dppz)]
2+ (where
bpy = 2,2-bipyridine and dppz = dipyridophenazine) (Fig. 19a)
binds to DNA which results in an enhancement of luminescence
attributed to a metal–ligand charge-transfer (MLCT) from the
ruthenium atom to a primarily ligand (dppz) based p* orbital.106
This 1MLCT excited state decays via intersystem crossing to a
3MLCT excited state primarily localised on the phenazine nitro-
gen atoms. When the complex is in aqueous environments water
quenches this excited state by hydrogen bonding with the
phenazine nitrogen atoms but when the dppz is shielded from
water the complex is luminescent.107
In similar fashion to its interaction with DNA the interaction of
[Ru(bpy)2(dppz)]
2+ with Ab fibrils also results in a change in the
polarity of the microenvironment resulting in enhanced lumines-
cence (Fig. 19c).108 The use of a metal based luminescent probe with
a long-lived excited state has potential advantages over more con-
ventional dyes such as ThT. The relatively long photoluminescent
lifetime of [Ru(bpy)2(dppz)]
2+ bound to Ab fibrils (185 ns) can be
used to diﬀerentiate between the competitive binding of other
molecules with shorter fluorescent lifetimes. The dissociation con-
stant for the binding of [Ru(bpy)2dppz]
2+ to Ab fibrils is 2.1 mMwith
a binding stoichiometry of 2.6 Ab monomers per [Ru(bpy)2dppz]
2+.
Computational methods that combines molecular docking and all
atommolecular dynamics simulation predicted that a hydrophobic
cleft between Val18 and Phe20 was a likely binding site with the
side chains of these two amino acid residues interacting with the
dppz functional group via CH–p and p–p interactions (Fig. 19b).109
The versatility and potential of this family of ruthenium complexes
as unconventional probes of protein aggregation is highlighted by
the use of the 1,10-phenanthroline analogue, [Ru(phen)2dppz]
2+
(where phen = 1,10-phenanthroline), a probe to monitor the
fibrilisation of a-syn, a protein associated with Parkinson’s
disease, in neuroglioma cells.110
8 Metal complexes to inhibit
aggregation and toxicity of amyloid-b
(Ab)
Amyloid-b peptides possess moderate aﬃnity for copper(II),
copper(I) and zinc(II). The interaction of Ab with CuII involves
Fig. 18 General structure of complexes containing curcumin (HL24); left:
fac-[Re(CO)3 (PPh3) L
24] a ‘‘2+1’’ complex, right cis–trans-
[Re(CO)2(PPh3)2L
24] ‘‘2+1+1’’ complex, M = ReI or 99mTcI.
Fig. 19 (a) Structure of the ruthenium polypyridyl complex,
[Ru(bpy)2(dppz)]
2+. (b) Representation of a molecular dynamics simulation
showing binding of [Ru(bpy)2(dppz)]
2+ to an Ab fibril. The simulation
predicts that binding occurs in a hydrophobic cleft formed between
Val18 and Phe20. (c) Photoluminescence spectra of [Ru(bpy)2(dppz)]
2+
incubated with Ab40 (red), Ab25–35 (blue), and buffer (black). Inset shows
TEM image of Ab25–35 fibrils (scale bar = 200 nm). Images adapted with
permission from N. P. Cook, M. Ozbil, C. Katsampes, R. Prabhakar and A. A.
Marti, J. Am. Chem. Soc., 2013, 135, 10810–10816. Copyright 2013 Amer-
ican Chemical Society.
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coordination of the metal ion to imidazole residues on His6,
His13, and His14 and alters the aggregation and toxicity
profiles of the peptide.28,31,33,111–115 The resulting CuII–Ab
complexes are redox active and lead to the production of toxic
reactive oxygen species.116 Modification of the CuII and ZnII
binding site of Ab has the potential to mitigate toxicity and
inhibit amyloid formation. An innovative approach of the metal
binding properties of Ab is to use metal complexes with
kinetically inert metal ions to form stable coordinate bonds
with the histidine residues that are involved in coordination to
CuII and ZnII. The challenge is to achieve selectivity for the
histidine residues and this has, in part, been achieved by using
PtII complexes with hydrophobic phenanthroline ligands and
two monodentate co-ligands poised for substitution reactions
with the N-donors of the imidazole residues of histidine.
The aggregation and neurotoxicity of Ab is modulated by the
addition of [PtIICl2(phen)] (where phen = 1,10-phenanthroline)
and similar complexes (Fig. 20).117 These PtII complexes target
the metal binding site of Ab by exchange of the monodentate
chloride ligands followed by coordination of the PtII ion to
the imidazole functional group in the histidine residues to give
[PtII(phen)–Ab]2+ adducts. It is thought that the complexes target
the N-terminal domain of Ab through p–p interactions between
the aromatic phen ligand and the aromatic residues of the peptide
(Phe4, Tyr10 and Phe19) that span the CuII binding site. The
coordination of the [Pt(phen)]2+ complexes to Ab inhibits the
aggregation of the peptide and leads to precipitation of amorphous
aggregates rather than amyloid fibrils. The formation of the [PtII-
(phen)–Ab]2+ adducts results inhibition of the neurotoxicity of Ab and
protection against Ab induced synaptotoxicity in mouse hippocam-
pal tissue.117 The non-covalent interactions between the aromatic
phen ligand and aromatic residues of amino acids in the Ab peptide
lead to an acceleration in the rate of reaction as demonstrated by the
reaction of [PtCl2(phen)] with the shorter variant Ab16 (t1/2E 4 min)
when compared to the platination of comparable N-donor
ligands.118 The formation of [PtII(phen)–Ab16]
2+ adducts alters
the CuII and ZnII binding properties of Ab16 and thus changes the
aggregation and toxicity profiles of the peptide.119 Following the
reaction of Ab42 with a water soluble sulfonated analogue of
[PtCl2(phen)], [PtCl2(4,7-diphenyl-[1,10]phenanthroline disulfonate)],
several products containing a ratio of 1 :1 platinum to Ab42 were
identified by mass spectrometry. X-ray absorption spectroscopy in
combination with theoretical calculations (density functional theory)
suggested the major component was a square planar PtII complex,
[PtII((4,7-diphenyl-[1,10]-phenanthroline disulfonate))(hist)Cl]+,
and the EXAFS refinement gave bond lengths of Pt–N(phen),
1.993(5) Å, Pt–N(imidazole), 2.03(1) Å and Pt–Cl and 2.235(7) Å.
In contrast to [PtCl2(phen)] and its analogues, the reaction of
cis-[Pt(NH3)2Cl2] with Ab42 results in a mixture of products that
primarily involve coordination to the sulfur atom of Met35.
Similar mixed RuII and PtII complexes also prevent the aggregation
of Ab42 as does a cyclometalated Pt
II complex, [Pt(Cl)(dimethyl-
sulfoxide)(2-phenyl-5-methylpyridine)], which binds to Ab28.
120,121
The binding of the platinum complex to the peptide does not
preclude the coordination of CuII to Ab28 but does result in a
complex where the CuII is in a different coordination environ-
ment.122 The interaction of this organometallic complex with
this shorter form of the Ab peptide also inhibits ZnII induced
aggregation.123 A strategy of combining the Ab binding ability
of platinum complexes containing aromatic ligands with the
copper(II) and zinc(II) binding properties of the tetraazamacro-
cyclic chelator cyclen has led to the synthesis of cyclen–Pt(bpy)
conjugates (where bpy = 2,2-bipyridine). Upon interaction with
Ab40 the Pt
II ion of these conjugates coordinates to His14/13 and
the macrocyclic ligand is able to sequester CuII and ZnII. The
simultaneous metal chelation and coordinate bondmodification
of the peptide alter the aggregation of Ab40.
124
Each of these platinum(II) complexes are likely to have poor
bioavailability and blood–brain barrier penetration and this has
the potential to compromise their clinical development for the
treatment of neurodegeneration. The desire to provide orally
bioavailable platinum(II) complexes with the potential to alter Ab
aggregation led to the synthesis of a platinum(IV) complex with a
specifically designed benzoimidazole quinoline ligand (L25)
(Fig. 21). The idea of using a PtIV complex as a pro-drug activated
by in vivo reduction to a PtII species was inspired by the similar
approach used to make orally bio-available and less toxic platinum
complexes for the treatment of cancer (Satraplatin). Complex
[PtIVCl4L
25] was administered orally to the APP/PS1 mouse model
of amyloid pathology. Analysis of the brain tissue following treat-
ment revealed a 40% reduction in Ab42 levels and a reduction in Ab
plaques when compared to untreated animals (Fig. 21).125
The potential of metal complexes with kinetically inert d6
complexes to inhibit Ab amyloid has been extended to IrIII,
RhIII, and RuII complexes. Iridium(III) and rhodium(III) com-
plexes with orthometallated phenylpyridine (ppy) ligands,
[M(ppy)2(OH2)2]
+ (where M = RhIII or IrIII) (Fig. 20), inhibit the
aggregation of Ab40 with [Rh(ppy)2(OH2)2]
+ the most eﬀective,
inhibiting aggregation at concentrations of 5 mM. It is likely
that exchange of the aqua ligands is followed by coordination of
the metal ion to the imidazole side chains of the histidine
residues in Ab40. The complexes formed from [Ir(ppy)2(OH2)2]
+
in the presence of Ab40 are luminescent and the emission
intensity (lem = 491 nm) is higher for aggregated [Ab40–Ir(ppy)2]
+
complexes when compared to the monomeric form suggesting
this system could be used as an alternative to conventional
Fig. 20 The structures of [PtCl2(phen)], [PtCl(dimethylsulfoxide)(2-
phenyl-5-methylpyridine)] and [M(ppy)2(OH2)2]
+ (where M = RhIII or IrIII).
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fluorescent dyes for monitoring fibrilisation.126 A series of
ruthenium(II) complexes also interact with Ab peptides and
pioneering studies have identified some interesting substitu-
tion chemistry. The reaction of fac-[Ru(CO)3Cl2(1,3-thiazole)]
(Fig. 22) with Ab28 results in a mixture where the predominant
product identified by electrospray mass spectrometry is of the
composition [Ru(CO)3–Ab28]
2+ and similar complexes were
identified when longer Ab42 replaced Ab28. The coordination
of the [Ru(CO)3]
2+ fragment to Ab28 results in dramatic changes
to the 1H NMR spectrum with significant broadening of signals
attributed to the three histidine residues and tyrosine-10 impli-
cating the histidine residues in coordination to the RuII.127 A
ruthenium(III) monoanionic complex with two 2-aminothiazole
N-bound ligands and four chloride ligands (PMRU20) (Fig. 22)
was found to offer protection against Ab induced toxicity in rat
primary cortical neurons. Interestingly two other structurally
related RuIII complexes, NAMI A and KP1019 (Fig. 22), offered
little to no protection. The difference in reactivity between
these complexes is intriguing and warrants further investiga-
tion.128 The reaction of selected ruthenium complexes with
proteins involved in the pathology of type II diabetes (human
islet amyloid polypeptide) and prion diseases (PrP106–126) also
results in significant changes to the aggregation of the respec-
tive proteins. This further highlights the potential of coordinate
bond formation with kinetically inert metal ions to act as novel
inhibitors of amyloid formation.129,130
9 Conclusions
The full details of the role Ab plaques, oligomers, tau and neuro-
fibrillary tangles play in cognitive impairment in Alzheimer’s disease
remains a mystery. What is known about the extracellular amyloid
deposits evident in the cortex of subjects with the disease is that they
contain relatively high concentrations of aggregated amyloid-b
protein, a 39–43 amino acid fragment derived from the amyloid
precursor protein. Our understanding of the structure and actual
function of both Ab and APP remains incomplete. It is possible that
there is still much to learn about the generation, clearance and
toxicity of Ab as well as the molecular dynamics involving Ab
monomers, oligomers and plaques. Significant progress in the last
decade has led to the development of molecular tracers that can
offer insight into the deposition of amyloid in the brain of living
patients using non-invasive PET imaging. The results of pioneering
multi-centre studies using PET tracers to detect amyloid in large
patient cohorts are emerging and providing valuable insights into
the relationship between amyloid and cognition.131–133
There are several radioactive isotopes of copper that have the
potential to be of use in PET imaging and technetium-99m
continues to be the radioisotope of choice for SPECT imaging.
In principle, ligands designed to bind to amyloid plaques and
form stable copper or technetium complexes have the potential
to extend the capabilities of amyloid imaging. A new ligand
based on a bis(thiosemicarbazone) framework with appended
plaque targeting functional group and hybrid thiosemicarbazone–
styrylpyridine ligands have shown some promise as ligands for
copper radiopharmaceuticals. A wide range of Tc complexes
designed to bind to Ab plaques is discussed in the review. The
‘‘piano stool’’ complex, [99mTcIL21] (Fig. 21), shows significant
potential and warrants further investigation.
Luminescent ruthenium and iridium metal complexes with
long fluorescent lifetimes that undergo significant changes to their
electronic spectra upon binding to Ab fibrils have potential as
useful probes to gain increased insight into the molecular aspects
of amyloid formation and aggregation. The interaction of the
hydrophobic complex [Ru(bpy)2(dppz)]
2+ with Ab40 results in a
dramatic change in the photoluminescence of the complex and
the long fluorescent life-time could be of use in competitive
binding assays with other small molecules. An innovative approach
at altering the metal-binding properties, toxicity and aggregation
profiles of Ab is to use metal complexes of kinetically inert metal
ions to form coordinate bonds to the histidine residues in the
metal-binding domain of Ab. Complexes with the kinetically inert
ions, PtII, RuII, IrIII and RhIII all interact with Ab peptides of varying
length to give adducts that have altered toxicity and propensity to
aggregate. The viability of metal complexes to be therapeutically
useful inhibitors of amyloid formation and Ab toxicity will be
dependent on them satisfying the stringent and challenging
requirements of therapeutic agents.134
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